Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 946 results for "for merck"

Sun Pharma gains; becomes first to license drug from innovator
Reuters

Merck out-licenses psoriasis drug candidate

News Editor Merck (MRK -0.4%) sells an exclusive worldwide license to Mumbai-based Sun Pharmaceutical Industries for tildrakizumab, a humanized mAb for the treatment of chronic plaque psoriasis. Under the terms of the agreement, Merck will ... Seeking Alpha, 2 hours ago
[x]  

329 images for for merck

Pharma Letter, 21 hours ago
Business Today India, 3 days ago
Yahoo! Finance, 21 hours ago
Reuters, 1 day ago
NDTV Profit, 3 days ago
Jutia Group, 4 days ago
Livemint.com, 2 days ago
Livemint.com, 3 days ago
Money Today, 5 days ago
Business Standard India, 9 minutes ago
Business Standard

Merck to buy US group for €13bn

Drug and chemical maker Merck KGaA agreed yesterday to acquire US-based Sigma-Aldrich Corp for $17 billion (€13.25 billion) in cash to boost its lab supplies business, the biggest takeover in the German group's history. The deal helps Merck, 70 ...
 Irish Times4 hours ago Merck to buy life sciences services major Sigma-Aldrich for $17B  VC Circle7 hours ago RLPC-Banks line up $15.6 bn loan for Merck's Sigma-Aldrich buy  Reuters UK10 hours ago How Will Sigma-Aldrich Acquisition Be Accretive for Merck KGaA?  Bidness Etc1 day ago
[x]  

The FDA Said It Has Granted Accelerated Approval To Merck's KeytrudaIs - Is Merck Worth Investing In?

Summary After seven years of waiting Merck has finally landed the FDA's approval on a cancer treatment drug. In layman terms, the drug stops cancer cells from attaching themselves to a protein and make diseased cells appear normal and healthy to ...
 Seeking Alpha4 hours ago Merck osteoporosis drug passes trial, but side effects hover  Reuters1 week ago FDA approves Merck drug, first in new cancer drug class  Economic Times2 weeks ago U.S. FDA approves Merck insomnia drug  Reuters1 month ago

Merck to acquire 100% stake in Sigma-Aldrich

Merck KGaA, a Germany-based pharmaceutical, chemicals and life science company, has entered into a definitive agreement to acquire 100% stake in Sigma-Aldrich Corporation, a US-based producer and seller of biochemicals, organic and inorganic ...
 Individual.com7 hours ago Merck KGaA in $11 billion deal for Sigma-Aldrich  Pharma Letter1 day ago

Biggest takeover for Germany's Merck as it agrees $17bn Sigma-Aldrich deal

Drugs and chemicals maker Merck has agreed to buy US company Sigma-Aldrich for $17bn (€13.24) in cash to boost its lab supplies business, the biggest takeover in the German group's history. Drugs and chemicals maker Merck has agreed to buy US ...
 Irish Independent21 hours ago Biggest takeover for Germanys Merck as it agrees $17bn Sigma-Aldrich deal  Big News Network12 hours ago

Research and Markets: Global Pneumococcal Vaccines Market 2014-2018: GlaxoSmithKline, Merck & Pfizer Dominate the Industry

DUBLIN--(BUSINESS WIRE)--Sep. 23, 2014-- Research and Markets (http://www.researchandmarkets.com/research/b9xlc3/global) has announced the addition of the "Global Pneumococcal Vaccines Market 2014-2018" report to their offering. The Global ...
 BusinessWeek14 hours ago Global Pneumococcal Vaccines Market 2014-2018: GlaxoSmithKline, Merck & Pfizer Dominate the Industry  Individual.com14 hours ago RESEARCH AND MARKETS : Global Pneumococcal Vaccines Market 2014-2018: GlaxoSmithKline, Merck & Pfizer Dominate the Industry  4 Traders14 hours ago
[x]  

Merck's buy helps shift away from drugs

Phil Serafino Paris MERCK has agreed to buy Sigma-Aldrich for $17 billion (R188bn) in cash to expand in chemicals used in research laboratories and drug making. The German drug and chemical company would pay $140 a share, 37 percent more than ...
 IOL16 hours ago

Regulatory Approval, Presentation of Data, Appointment, Clinical Study Results, and Increase in Quarterly Dividend - Research Reports on Johnson & Johnson, Merck, Medtronic, Amgen and Covidien

Today, released its research reports regarding Johnson & Johnson (NYSE: JNJ), Merck & Co., Inc. (NYSE: MRK), Medtronic, Inc. (NYSE: MDT), Amgen Inc. (NASDAQ: AMGN) and Covidien plc (NYSE: COV). Private wealth members receive these notes ahead of ...
 Industrial Info Financials9 hours ago
[x]  

Merck's Phase III osteoporotic fracture study meets primary endpoints

Merck has announced data from the Phase III fracture outcomes study for odanacatib in postmenopausal women with osteoporosis. In the Long-Term Odanacatib Fracture Trial, or LOFT, odanacatib met its primary endpoints and significantly reduced the ...
 Individual.com1 day ago Merck announces first data from Phase III type 2 diabetes development program  Individual.com1 day ago MSD Presents First Phase 3 Data in Japanese Patients for Omarigliptin, an Investigational Once-Weekly DPP-4 Inhibitor for Type 2 Diabetes  Andhra News5 days ago

Sun Pharma and Merck Enter into Tildrakizumab Licensing Agreement

Merck and Sun Pharma through their respective subsidiaries, reported a licensing agreement for Merck's investigational therapeutic antibody candidate, tildrakizumab, (MK-3222). In its release on Sept. 17, the Company said that tildrakizumab is ...
 Individual.com1 day ago Sun Pharma and Merck & Co. Ink Licensing Pact for Tildrakizumab  Individual.com1 day ago Merck : Sun Pharma and Merck & Co. Ink Licensing Pact for Tildrakizumab  4 Traders1 day ago Sun Pharma, Merck ink licensing pact for Tildrakizumab  Myiris6 days ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less